Drug Profile

REV 0100

Alternative Names: REV-0100

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cornell University
Developer Cornell University; ReVision Therapeutics
Class Eye disorder therapies
Mechanism of Action Lipid modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Stargardt disease
New Molecular Entity Yes

Highest Development Phases

No development reported Stargardt disease

Most Recent Events

28 Apr 2025 No recent reports of development identified for phase-I development in Stargardt disease in Unknown
28 Nov 2024 No recent reports of development identified for preclinical development in Stargardt disease in USA
17 Mar 2022 Phase-I clinical trials in Stargardt disease

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com